JPWO2022268983A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022268983A5 JPWO2022268983A5 JP2023576235A JP2023576235A JPWO2022268983A5 JP WO2022268983 A5 JPWO2022268983 A5 JP WO2022268983A5 JP 2023576235 A JP2023576235 A JP 2023576235A JP 2023576235 A JP2023576235 A JP 2023576235A JP WO2022268983 A5 JPWO2022268983 A5 JP WO2022268983A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- functional variant
- immunocytokine
- seq
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21181271 | 2021-06-23 | ||
| EP21181271.4 | 2021-06-23 | ||
| EP22163748 | 2022-03-23 | ||
| EP22163748.1 | 2022-03-23 | ||
| PCT/EP2022/067236 WO2022268983A2 (en) | 2021-06-23 | 2022-06-23 | Interleukin-15 based immunocytokines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024524891A JP2024524891A (ja) | 2024-07-09 |
| JPWO2022268983A5 true JPWO2022268983A5 (https=) | 2025-06-10 |
| JP2024524891A5 JP2024524891A5 (https=) | 2025-06-10 |
Family
ID=82361370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023576235A Pending JP2024524891A (ja) | 2021-06-23 | 2022-06-23 | インターロイキン－１５に基づく免疫サイトカイン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240294594A1 (https=) |
| EP (1) | EP4359428A2 (https=) |
| JP (1) | JP2024524891A (https=) |
| KR (1) | KR20240024242A (https=) |
| AU (1) | AU2022296794A1 (https=) |
| BR (1) | BR112023027312A2 (https=) |
| CA (1) | CA3221886A1 (https=) |
| IL (1) | IL309533A (https=) |
| MX (1) | MX2023015444A (https=) |
| WO (1) | WO2022268983A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016002614B8 (pt) | 2013-08-08 | 2023-11-07 | Hopitaux Paris Assist Publique | Imunocitoquina e composição farmacêutica |
| EP4069738A1 (en) * | 2019-12-06 | 2022-10-12 | SOTIO Biotech a.s. | Humanized cldn18.2 antibodies |
| WO2025177263A1 (en) * | 2024-02-25 | 2025-08-28 | Biohaven Therapeutics Ltd. | Myostatin-binding proteins |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| US20100082438A1 (en) | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| AU2009336800A1 (en) | 2009-01-07 | 2011-07-21 | Philogen S.P.A. | Cancer treatment |
| CA2902739C (en) * | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| EP2988784A1 (en) | 2013-04-25 | 2016-03-02 | Philogen S.p.A. | Antibody-drug conjugates |
| AU2016365114A1 (en) | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| CN110214147A (zh) * | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| JP2021516045A (ja) | 2018-02-28 | 2021-07-01 | ファイザー・インク | Ｉｌ−１５バリアントおよびその使用 |
| JP2021514625A (ja) * | 2018-03-01 | 2021-06-17 | グリコトープ ゲーエムベーハー | 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物 |
| CA3097625A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| AU2019359475A1 (en) * | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| US11738050B2 (en) | 2019-02-01 | 2023-08-29 | Regents Of The University Of Minnesota | Compounds binding to fibroblast activation protein alpha |
| WO2021057826A1 (zh) * | 2019-09-25 | 2021-04-01 | 北京志道生物科技有限公司 | 一种重组白介素-15类似物 |
-
2022
- 2022-06-23 BR BR112023027312A patent/BR112023027312A2/pt unknown
- 2022-06-23 KR KR1020247002543A patent/KR20240024242A/ko active Pending
- 2022-06-23 US US18/573,397 patent/US20240294594A1/en active Pending
- 2022-06-23 EP EP22736247.2A patent/EP4359428A2/en active Pending
- 2022-06-23 CA CA3221886A patent/CA3221886A1/en active Pending
- 2022-06-23 AU AU2022296794A patent/AU2022296794A1/en active Pending
- 2022-06-23 MX MX2023015444A patent/MX2023015444A/es unknown
- 2022-06-23 JP JP2023576235A patent/JP2024524891A/ja active Pending
- 2022-06-23 IL IL309533A patent/IL309533A/en unknown
- 2022-06-23 WO PCT/EP2022/067236 patent/WO2022268983A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7245815B2 (ja) | 改変されたＦｃ領域を含む抗原結合分子 | |
| JP7698004B2 (ja) | ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体 | |
| US11820793B2 (en) | Drug containing carrier into cell for forming immune complex | |
| AU2015353409B2 (en) | Heterodimeric antibodies that bind CD3 and tumor antigens | |
| CN104244980B (zh) | 经由FcγIIB促进抗原消除的抗原结合分子 | |
| CN105764922B (zh) | 多肽异源多聚体的制备方法 | |
| CN105102618B (zh) | 异源二聚化多肽 | |
| JP2024534454A (ja) | 抗ｃｄ３抗体 | |
| JP2021080260A (ja) | ポリペプチド異種多量体の製造方法 | |
| Park et al. | The highly evolvable antibody Fc domain | |
| JP2020079296A (ja) | 抗原の消失を促進する抗原結合分子 | |
| JP2020059700A (ja) | Ｆｃ領域改変体 | |
| JP2022033769A (ja) | 強化されたアゴニスト活性を有する、Ｆｃが遺伝子操作を受けた抗ＴＮＦＲスーパーファミリーメンバー抗体及びその使用方法 | |
| AU2012233313A1 (en) | Method for altering plasma retention and immunogenicity of antigen-binding molecule | |
| AU2017308590A1 (en) | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions | |
| CN103827300A (zh) | 异源二聚化多肽 | |
| CN103703129A (zh) | 改变抗原结合分子的血浆中滞留性和免疫原性的方法 | |
| WO2023164288A2 (en) | Targeted cytokines and methods of use thereof | |
| JP2023106564A (ja) | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 | |
| Mimoto et al. | Fc engineering to improve the function of therapeutic antibodies | |
| WO2024086617A2 (en) | Ph-dependent anti-cd3 antibodies and methods relating thereto | |
| JP2021511298A5 (https=) | ||
| JPWO2022268983A5 (https=) | ||
| JPWO2022047243A5 (https=) | ||
| JPWO2021216956A5 (https=) |